




Instance: composition-en-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: CompositionUvEpi
Title: "Composition for nilemdo Package Leaflet"
Description:  "Composition for nilemdo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/20/1425/001 - 011"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - nilemdo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol type="1">
<li>What Nilemdo is and what it is used for</li>
<li>What you need to know before you take Nilemdo</li>
<li>How to take Nilemdo</li>
<li>Possible side effects</li>
<li>How to store Nilemdo</li>
<li>Contents of the pack and other information</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. What nilemdo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What nilemdo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Nilemdo is and how it works</p>
<p>Nilemdo is a medicine that lowers levels of bad cholesterol (also
called LDL-cholesterol ), a type of fat, in the blood.</p>
<p>Nilemdo contains the active substance bempedoic acid, which is
inactive until it enters the liver where it is changed to its active
form. Bempedoic acid decreases the production of cholesterol in the
liver and increases the removal of LDL-cholesterol from the blood by
blocking an enzyme (ATP citrate lyase) needed for the production of
cholesterol.</p>
<p>What Nilemdo is used for</p>
<p>Nilemdo is given to adults with primary hypercholesterolaemia or
mixed dyslipidaemia, which are conditions that cause a high cholesterol
level in the blood. It is given in addition to a cholesterol- lowering
diet.</p>
<p>Nilemdo is given:</p>
<ul>
<li>if you have been using a statin (such as simvastatin, a commonly
used medicine that treats high cholesterol) and this does not lower your
LDL-cholesterol sufficiently;</li>
<li>alone or together with other cholesterol-lowering medicines when
statins are not tolerated or cannot be used.</li>
</ul>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Nilemdo:</p>
<ul>
<li>if you are allergic to bempedoic acid or any of the other
ingredients of this medicine (listed in section 6);</li>
<li>if you are pregnant;</li>
<li>if you are breast-feeding;</li>
<li>if you take more than 40 mg of simvastatin daily (another medicine
used to lower cholesterol).</li>
</ul>
<p>Warnings and precautions</p>
<p>Talk to your doctor or pharmacist before taking Nilemdo:</p>
<ul>
<li>if you ever had gout;</li>
<li>if you have severe kidney problems;</li>
<li>if you have severe liver problems.</li>
</ul>
<p>Your doctor may do a blood test before you start taking Nilemdo. This
is to check how well your liver is working.</p>
<p>Children and adolescents</p>
<p>Do not give Nilemdo to children and adolescents under 18 years of
age. The use of Nilemdo has not been studied in this age group.</p>
<p>Other medicines and Nilemdo</p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken
or might take any other medicines. In particular, tell your doctor if
you are taking medicine(s) with any of the following active
substances:</p>
<ul>
<li>atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin,
simvastatin (used to lower cholesterol and known as statins). The risk
of muscle disease may increase when taking both a statin and Nilemdo.
Tell your doctor immediately about any unexplained muscle pain,
tenderness or weakness.</li>
<li>bosentan (used to manage a condition called pulmonary artery
hypertension).</li>
<li>fimasartan (used to treat high blood pressure and heart
failure).</li>
<li>asunaprevir, glecaprevir, grazoprevir, voxilaprevir (used to treat
hepatitis C).</li>
</ul>
<p>Pregnancy and breast-feeding</p>
<p>Do not take this medicine if you are pregnant, trying to get
pregnant, or think you may be pregnant, as there is a possibility that
it could harm an unborn baby. If you get pregnant while taking this
medicine, call your doctor immediately and stop taking Nilemdo.</p>
<ul>
<li>Pregnancy Before starting treatment, you should confirm you are not
pregnant and are using effective contraception, as advised by your
doctor. If you use contraceptive pills and suffer from an episode of
diarrhoea or vomiting that lasts more than 2 days, you must use an
alternative method of contraception (e.g. condoms, diaphragm) for 7 days
following resolution of symptoms.</li>
</ul>
<p>If, after you have started treatment with Nilemdo, you decide that
you would like to become pregnant, tell your doctor, as your treatment
will need to be changed.</p>
<ul>
<li>Breast-feeding Do not take Nilemdo if you are breast-feeding because
it is not known if Nilemdo passes into milk. Driving and using
machines</li>
</ul>
<p>Nilemdo has no or little influence on the ability to drive and use
machines.</p>
<p>Nilemdo contains lactose and sodium</p>
<p>If you have been told by your doctor that you have an intolerance to
some sugars, contact your doctor before taking this medicine.</p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per tablet,
that is to say essentially sodium- free .</p>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has
told you. Check with your doctor or pharmacist if you are not sure.</p>
<p>The recommended dose is one tablet once daily.</p>
<p>Swallow the tablet whole with food or between meals.</p>
<p>If you take more Nilemdo than you should</p>
<p>Contact your doctor or pharmacist immediately.</p>
<p>If you forget to take Nilemdo</p>
<p>If you notice that you forgot:</p>
<ul>
<li>a dose late in a day, take the missed dose and take the next dose at
your regular time the next day.</li>
<li>the previous day s dose, take your tablet at the regular time and do
not make up for the forgotten dose.</li>
</ul>
<p>If you stop taking Nilemdo</p>
<p>Do not stop taking Nilemdo without your doctor s permission as your
cholesterol may rise again.</p>
<p>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</p>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</p>
<p>Side effects can occur with the following frequencies:</p>
<p>Common (may affect up to 1 in 10 people)</p>
<ul>
<li>lower number of red blood cells (anaemia)</li>
<li>increased levels of uric acid in blood, gout</li>
<li>pain in shoulders, legs, or arms</li>
<li>blood test results indicating liver abnormalities</li>
</ul>
<p>Uncommon (may affect up to 1 in 100 people)</p>
<ul>
<li>decreased haemoglobin (a protein in red blood cells that carries
oxygen)</li>
<li>raised creatinine and blood urea nitrogen (laboratory tests of
kidney function)</li>
<li>decreased glomerular filtration rate (a measure of how well your
kidneys are working)</li>
</ul>
<p>Reporting of side effects</p>
<p>If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. You can
also report side effects directly via the national reporting system
listed in Appendix V. By reporting side effects, you can help provide
more information on the safety of this medicine.</p>
 </div>"""      
        
* section[=].section[+]
  * title = "5. How to store nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.</p>
<p>Do not use this medicine after the expiry date which is stated on the
blister and carton after EXP. The expiry date refers to the last day of
the month.</p>
<p>This medicine does not require any special storage conditions.</p>
<p>Do not throw away any medicine via wastewater or household waste. Ask
your pharmacist how to throw away medicines you no longer use. These
measures will help protect the environment.</p>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Nilemdo contains</p>
<ul>
<li>The active substance is bempedoic acid. Each film-coated tablet
contains 180 mg of bempedoic acid.</li>
<li>The other ingredients are:</li>
</ul>
<ul>
<li>lactose monohydrate (see end of section 2 under Nilemdo contains
lactose and sodium )</li>
<li>microcrystalline cellulose (E460)</li>
<li>sodium starch glycolate (Type A grade) (see end of section 2 under
Nilemdo contains lactose and sodium )</li>
<li>hydroxypropyl cellulose (E463)</li>
<li>magnesium stearate (E470b)</li>
<li>silica, colloidal anhydrous (E551)</li>
<li>partially hydrolysed poly(vinyl alcohol) (E1203), talc (E553b),
titanium dioxide (E171), macrogol/PEG (E1521)</li>
</ul>
<p>What Nilemdo looks like and contents of the pack</p>
<p>Film-coated tablets are white to off-white, oval, debossed with 180
on one side and ESP on the other side. Tablet dimensions: 13.97 mm 6.60
mm 4.80 mm.</p>
<p>Nilemdo is supplied in plastic/aluminium blisters in cartons of 10,
14, 28, 30, 84, 90, 98 or 100 film- coated tablets or unit dose blisters
in cartons of 10 x 1, 50 x 1 or 100 x 1 film-coated tablets.</p>
<p>Not all pack sizes may be marketed in your country.</p>
<p>Marketing Authorisation Holder</p>
<p>Daiichi Sankyo Europe GmbH Zielstattstrasse 81379 Munich Germany</p>
<p>Manufacturer</p>
<p>Daiichi Sankyo Europe GmbH Luitpoldstrasse 1 85276 Pfaffenhofen
Germany</p>
<p>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</p>
<p>Belgi /Belgique/Belgien Daiichi Sankyo Belgium N.V.-S.A T l/Tel:
+32-(0) 2 227 18 Lietuva Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808
0</p>
<p>Daiichi Sankyo Europe GmbH .: +49-(0) 89 7808 0 Luxembourg/Luxemburg
Daiichi Sankyo Belgium N.V.-S.A T l/Tel: +32-(0) 2 227 18 esk republika
Zentiva, k.s. Tel: +420 267 241 Magyarorsz g Daiichi Sankyo Europe GmbH
Tel.: +49-(0) 89 7808 0 Danmark Daiichi Sankyo Europe GmbH Tlf: +49-(0)
89 7808 0 Malta Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0
Deutschland Daiichi Sankyo Deutschland GmbH Tel: +49-(0) 89 7808 0
Nederland Daiichi Sankyo Nederland B.V. Tel: +31-(0) 20 4 07 20 Eesti
Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Norge Daiichi Sankyo
Europe GmbH Tlf: +49-(0) 89 7808 0</p>
<p>Daiichi Sankyo Europe GmbH : +49-(0) 89 7808 0 sterreich Daiichi
Sankyo Austria GmbH Tel: +43 (0) 1 485 86 42 0 Espa a Daiichi Sankyo
Espa a, S.A. Tel: +34 91 539 99 Polska Daiichi Sankyo Europe GmbH Tel.:
+49-(0) 89 7808 0 France Daiichi Sankyo France S.A.S. T l: +33 (0) 1 55
62 14 Portugal Daiichi Sankyo Portugal, Unip. LDA Tel: +351 21
4232Hrvatska Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Rom nia
Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Ireland Daiichi Sankyo
Ireland Ltd Tel: +353-(0) 1 489 3Slovenija Daiichi Sankyo Europe GmbH
Tel: +49-(0) 89 7808 0 sland Daiichi Sankyo Europe GmbH S mi: +49-(0) 89
7808 0 Slovensk republika Zentiva, a.s. Tel: +421 2 3918 3Italia Daiichi
Sankyo Italia S.p.A. Tel: +39-06 85 2Suomi/Finland Daiichi Sankyo Europe
GmbH Puh/Tel: +49-(0) 89 7808 0</p>
<p>Daiichi Sankyo Europe GmbH : +49-(0) 89 7808 0 Sverige Daiichi Sankyo
Europe GmbH Tel: +49-(0) 89 7808 0 Latvija Daiichi Sankyo Europe GmbH
Tel: +49-(0) 89 7808 0 United Kingdom (Northern Ireland) Daiichi Sankyo
Europe GmbH Tel: +49-(0) 89 7808 0</p>
<p>This leaflet was last revised in {month YYYY}.</p>
<p>Other sources of information</p>
<p>Detailed information on this medicine is available on the European
Medicines Agency web site:</p>
 </div>"""      



Instance: composition-da-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: CompositionUvEpi
Title: "Composition for nilemdo Package Leaflet"
Description:  "Composition for nilemdo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/20/1425/001 - 011"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - nilemdo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen</p>
<ol type="1">
<li>Virkning og anvendelse</li>
<li>Det skal du vide, før du begynder at tage Nilemdo</li>
<li>Sådan skal du tage Nilemdo</li>
<li>Bivirkninger</li>
<li>Opbevaring</li>
<li>Pakningsstørrelser og yderligere oplysninger</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad er Nilemdo, og hvordan virker det?</p>
<p>Nilemdo er et lægemiddel, der sænker niveauet af det såkaldt
"dårlige" kolesterol (LDL-kolesterol), der er en type fedt i blodet.</p>
<p>Nilemdo indeholder det aktive stof bempedoinsyre, der først bliver
aktivt, når det når leveren, hvor det forandres til dets aktive form.
Bempedoinsyre sænker produktionen af kolesterol i leveren og øger
fjernelsen af LDL-kolesterol fra blodet ved at blokere et enzym
(ATP-citratlyase), der er nødvendigt for dannelsen af kolesterol.</p>
<p>Hvad anvendes Nilemdo til?</p>
<p>Nilemdo gives til voksne med primær hyperkolesterolæmi eller blandet
dyslipidæmi, som er sygdomme, der forårsager et højt kolesterolniveau i
blodet. Nilemdo gives i tillæg til kolesterolsænkende diæt.</p>
<p>Nilemdo gives:</p>
<ul>
<li><p>hvis du har brugt et statin (f.eks. simvastatin, et almindeligt
anvendt lægemiddel til behandling af forhøjet kolesterol), uden at det
har sænket dit LDL-kolesterol tilstrækkeligt</p></li>
<li><p>alene eller sammen med andre lipidsænkende midler, når statin
ikke tåles eller ikke kan anvendes.</p></li>
</ul>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Nilemdo:</p>
<ul>
<li><p>hvis du er allergisk over for bempedoinsyre eller et af de øvrige
indholdsstoffer i Nilemdo (angivet i punkt 6)</p></li>
<li><p>hvis du er gravid</p></li>
<li><p>hvis du ammer</p></li>
<li><p>hvis du tager over 40 mg simvastatin dagligt (et andet
kolesterolsænkende lægemiddel).</p></li>
</ul>
<p>Advarsler og forsigtighedsregler</p>
<p>Kontakt lægen eller apotekspersonalet, før du tager Nilemdo:</p>
<ul>
<li><p>hvis du tidligere har haft urinsyregigt</p></li>
<li><p>hvis du har alvorlige nyreproblemer</p></li>
<li><p>hvis du har alvorlige leverproblemer.</p></li>
</ul>
<p>Lægen vil måske tage en blodprøve, før du begynder at tage Nilemdo,
for at se, hvor godt din lever fungerer.</p>
<p>Børn og unge</p>
<p>Nilemdo må ikke gives til børn og unge under 18 år. Anvendelse af
Nilemdo er ikke undersøgt hos denne aldersgruppe.</p>
<p>Brug af anden medicin sammen med Nilemdo</p>
<p>Fortæl det altid til lægen eller apotekspersonalet, hvis du tager
anden medicin, for nylig har taget anden medicin eller planlægger at
tage anden medicin. Fortæl det især til lægen, hvis du tager lægemidler,
der indeholder nogen af følgende aktive stoffer:</p>
<ul>
<li><p>atorvastatin, fluvastatin, pitavastatin, pravastatin,
rosuvastatin eller simvastatin (såkaldte statiner, der sænker
kolesterolniveauet). Risikoen for muskelsygdom kan øges ved samtidig
anvendelse af et statin og Nilemdo. Sig det til lægen med det samme,
hvis du oplever uventet smerte, ømhed eller svaghed i musklerne</p></li>
<li><p>bosentan (til behandling af forhøjet blodtryk i
lungearterierne)</p></li>
<li><p>fimasartan (til behandling af forhøjet blodtryk og
hjertesvigt)</p></li>
<li><p>asunaprevir, glecaprevir, grazoprevir eller voxilaprevir (til
behandling af hepatitis C).</p></li>
</ul>
<p>Graviditet og amning</p>
<p>Du må ikke tage dette lægemiddel, hvis du er gravid, har mistanke om,
at du er gravid, eller planlægger at blive gravid, da det muligvis kan
være skadeligt for det ufødte barn. Hvis du bliver gravid, mens du tager
dette lægemiddel, skal du straks kontakte lægen og holde op med at tage
Nilemdo.</p>
<ul>
<li>Graviditet Inden du påbegynder behandling, skal du bekræfte, at du
ikke er gravid, og at du bruger sikker prævention som anvist af lægen.
Hvis du bruger p-piller og oplever diarré eller opkastning, der varer
mere end 2 dage, skal du bruge en anden præventionsmetode (f.eks. kondom
eller pessar) i 7 dage, efter at symptomerne har fortaget sig.</li>
</ul>
<p>Hvis du efter at være startet på Nilemdo beslutter, at du ønsker at
blive gravid, skal du sige det til lægen, da din behandling så skal
ændres.</p>
<ul>
<li>Amning Du må ikke tage Nilemdo, hvis du ammer, da det er ukendt, om
Nilemdo udskilles i modermælk.</li>
</ul>
<p>Trafik- og arbejdssikkerhed</p>
<p>Nilemdo påvirker ikke eller kun i ubetydelig grad evnen til at føre
motorkøretøj og betjene maskiner.</p>
<p>Nilemdo indeholder lactose og natrium</p>
<p>Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt
dig, at du ikke tåler visse sukkerarter.</p>
<p>Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr.
tablet, dvs. det er i det væsentlige natriumfrit.</p>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets
anvisning. Er du i tvivl, så spørg lægen eller apotekspersonalet.</p>
<p>Den anbefalede dosis er én tablet én gang dagligt.</p>
<p>Tabletten skal synkes hel og kan tages med eller uden mad.</p>
<p>Hvis du har taget for meget Nilemdo</p>
<p>Kontakt lægen eller apotekspersonalet med det samme.</p>
<p>Hvis du har glemt at tage Nilemdo</p>
<p>Hvis du opdager, at du har glemt:</p>
<ul>
<li><p>at tage din dosis sent på dagen, skal du tage den glemte dosis og
tage den næste dosis på det sædvanlige tidspunkt næste dag.</p></li>
<li><p>at tage din dosis dagen før, skal du tage din nye tablet på det
sædvanlige tidspunkt; du må ikke tage en dobbeltdosis som erstatning for
den glemte dosis.</p></li>
</ul>
<p>Hvis du holder op med at tage Nilemdo</p>
<p>Du må ikke holde op med at tage Nilemdo uden lægens godkendelse, da
dit kolesterol kan stige igen.</p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl
om.</p>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men
ikke alle får bivirkninger.</p>
<p>Bivirkninger kan optræde med følgende hyppigheder:</p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10
patienter)</p>
<ul>
<li><p>nedsat antal røde blodlegemer (anæmi)</p></li>
<li><p>øget urinsyre i blodet, urinsyregigt</p></li>
<li><p>smerter i skuldre, ben eller arme</p></li>
<li><p>unormale levertal i blodprøver</p></li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100
patienter)</p>
<ul>
<li><p>nedsat hæmoglobin (et protein i de røde blodlegemer, der
transporterer ilt)</p></li>
<li><p>forhøjet kreatinin og karbamid i blodet (laboratorietest for
nyrefunktion)</p></li>
<li><p>nedsat glomerulær filtrationshastighed (et mål for
nyrefunktionen)</p></li>
</ul>
<p>Indberetning af bivirkninger</p>
<p>Hvis du oplever bivirkninger, bør du tale med din læge eller
apotekspersonalet. Dette gælder også mulige bivirkninger, som ikke er
medtaget i denne indlægsseddel. Du eller dine pårørende kan også
indberette bivirkninger direkte til Lægemiddelstyrelsen via det
nationale rapporteringssystem anført i Appendiks V. Ved at indrapportere
bivirkninger kan du hjælpe med at fremskaffe mere information om
sikkerheden af dette lægemiddel.</p>
 </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.</p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på blisteren og
æsken efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned.</p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende
opbevaringen.</p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af
hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet
eller skraldespanden.</p>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Nilemdo indeholder:</p>
<ul>
<li><p>Aktivt stof: bempedoinsyre. Hver filmovertrukket tablet
indeholder 180 mg bempedoinsyre.</p></li>
<li><p>Øvrige indholdsstoffer:</p></li>
</ul>
<ul>
<li>lactosemonohydrat (se til sidst i pkt. 2 under "Nilemdo indeholder
lactose og natrium")</li>
<li>mikrokrystallinsk cellulose (E460)</li>
<li>natriumstivelsesglycolat (type A) (se til sidst i pkt. 2 under
"Nilemdo indeholder lactose og natrium")</li>
<li>hydroxypropylcellulose (E463)</li>
<li>magnesiumstearat (E470b)</li>
<li>vandfri kolloid silica (E551)</li>
<li>delvist hydrolyseret polyvinylalkohol (E1203), talcum (E553b),
titandioxid (E171), macrogol/PEG (E1521)</li>
</ul>
<p>Udseende og pakningsstørrelser</p>
<p>Filmovertrukne tabletter, der er hvide til offwhite, ovale og præget
med "180" på den ene side og "ESP" på den anden side. Tabletstørrelse:
13,97 mm × 6,60 mm × 4,80 mm.</p>
<p>Nilemdo fås i plast/aluminium-blisters i æsker med 10, 14, 28, 30,
84, 90, 98 eller 100 filmovertrukne tabletter eller enkeltdosisblisters
i æsker med 10 x 1, 50 x 1 eller 100 x 1 filmovertrukne tabletter.</p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført i
Danmark.</p>
<p>Indehaver af markedsføringstilladelsen</p>
<p>Daiichi Sankyo Europe GmbH Zielstattstrasse 81379 München
Tyskland</p>
<p>Fremstiller</p>
<p>Daiichi Sankyo Europe GmbH Luitpoldstrasse 1 85276 Pfaffenhofen
Tyskland</p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du
henvende dig til den lokale repræsentant for indehaveren af
markedsføringstilladelsen:</p>
<p>België/Belgique/Belgien Daiichi Sankyo Belgium N.V.-S.A Tél/Tel:
+32-(0) 2 227 18 Lietuva Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808
0 България Daiichi Sankyo Europe GmbH тел.: +49-(0) 89 7808 0
Luxembourg/Luxemburg Daiichi Sankyo Belgium N.V.-S.A Tél/Tel: +32-(0) 2
227 18 Česká republika Zentiva, k.s. Tel: +420 267 241 Magyarország
Daiichi Sankyo Europe GmbH Tel.: +49-(0) 89 7808 0 Danmark Daiichi
Sankyo Europe GmbH Tlf: +49-(0) 89 7808 0 Malta Daiichi Sankyo Europe
GmbH Tel: +49-(0) 89 7808 0 Deutschland Daiichi Sankyo Deutschland GmbH
Tel: +49-(0) 89 7808 0 Nederland Daiichi Sankyo Nederland B.V. Tel:
+31-(0) 20 4 07 20 Eesti Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808
0 Norge Daiichi Sankyo Europe GmbH Tlf: +49-(0) 89 7808 0 Ελλάδα Daiichi
Sankyo Europe GmbH Τηλ: +49-(0) 89 7808 0 Österreich Daiichi Sankyo
Austria GmbH Tel: +43 (0) 1 485 86 42 0 España Daiichi Sankyo España,
S.A. Tel: +34 91 539 99 Polska Daiichi Sankyo Europe GmbH Tel.: +49-(0)
89 7808 0 France Daiichi Sankyo France S.A.S. Tél: +33 (0) 1 55 62 14
Portugal Daiichi Sankyo Portugal, Unip. LDA Tel: +351 21 4232Hrvatska
Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 România Daiichi Sankyo
Europe GmbH Tel: +49-(0) 89 7808 0 Ireland Daiichi Sankyo Ireland Ltd
Tel: +353-(0) 1 489 3Slovenija Daiichi Sankyo Europe GmbH Tel: +49-(0)
89 7808 0 Ísland Daiichi Sankyo Europe GmbH Sími: +49-(0) 89 7808 0
Slovenská republika Zentiva, a.s. Tel: +421 2 3918 3Italia Daiichi
Sankyo Italia S.p.A. Tel: +39-06 85 2Suomi/Finland Daiichi Sankyo Europe
GmbH Puh/Tel: +49-(0) 89 7808 0 Κύπρος Daiichi Sankyo Europe GmbH Τηλ:
+49-(0) 89 7808 0 Sverige Daiichi Sankyo Europe GmbH Tel: +49-(0) 89
7808 0 Latvija Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 United
Kingdom (Northern Ireland) Daiichi Sankyo Europe GmbH Tel: +49-(0) 89
7808 0</p>
<p>Denne indlægsseddel blev senest ændret {måned ÅÅÅÅ}.</p>
<p>Andre informationskilder</p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det
Europæiske Lægemiddelagenturs hjemmeside <a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</p>
 </div>"""      



Instance: composition-pt-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: CompositionUvEpi
Title: "Composition for nilemdo Package Leaflet"
Description:  "Composition for nilemdo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/20/1425/001 - 011"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - nilemdo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #pt
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. FOLHETO INFORMATIVO"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. FOLHETO INFORMATIVO"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Folheto informativo: Informação para o utilizador"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Folheto informativo: Informação para o utilizador"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "O que contém este folheto"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "O que contém este folheto"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>O que contém este folheto:</p>
<ol type="1">
<li>O que é Nilemdo e para que é utilizado</li>
<li>O que precisa de saber antes de tomar Nilemdo</li>
<li>Como tomar Nilemdo</li>
<li>Efeitos indesejáveis possíveis</li>
<li>Como conservar Nilemdo</li>
<li>Conteúdo da embalagem e outras informações</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. O que é nilemdo e para que é utilizado"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. O que é nilemdo e para que é utilizado"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>O que é Nilemdo e como funciona</p>
<p>Nilemdo é um medicamento que baixa os níveis do colesterol “mau"
(também chamado “colesterol LDL"), um tipo de gordura, no sangue.</p>
<p>Nilemdo contém a substância ativa ácido bempedoico, que está inativa
até entrar no fígado, onde passa para a sua forma ativa. O ácido
bempedoico diminui a produção de colesterol no fígado e aumenta a
remoção do colesterol LDL do sangue através do bloqueio de uma enzima
(ATP citrato liase) necessária à produção de colesterol.</p>
<p>Para que é utilizado Nilemdo</p>
<p>Nilemdo é administrado a adultos com hipercolesterolemia primária ou
dislipidemia mista, que são doenças que causam um nível elevado de
colesterol no sangue. É administrado em complemento de uma dieta
redutora do colesterol.</p>
<p>Nilemdo é administrado:</p>
<ul>
<li><p>se tiver estado a utilizar uma estatina (como a sinvastatina, um
medicamento frequentemente utilizado para tratar o colesterol elevado) e
sem que esse tratamento tenha reduzido suficientemente o seu colesterol
LDL;</p></li>
<li><p>isoladamente ou em conjunto com outros medicamentos que reduzem o
colesterol quando as estatinas não são toleradas ou não podem ser
usadas.</p></li>
</ul>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. O que precisa de saber antes de tomar nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. O que precisa de saber antes de tomar nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Não tome Nilemdo</p>
<ul>
<li><p>se tem alergia ao ácido bempedoico ou a qualquer outro componente
deste medicamento (indicados na secção 6);</p></li>
<li><p>se está grávida;</p></li>
<li><p>se está a amamentar;</p></li>
<li><p>se tomar mais de 40 mg de sinvastatina por dia (outro medicamento
utilizado para baixar o nível do colesterol).</p></li>
</ul>
<p>Advertências e precauções</p>
<p>Fale com o seu médico ou farmacêutico antes de tomar Nilemdo:</p>
<ul>
<li><p>se alguma vez teve gota;</p></li>
<li><p>se sofre de problemas graves nos rins;</p></li>
<li><p>se sofre de problemas graves no fígado.</p></li>
</ul>
<p>O seu médico pode fazer-lhe uma análise ao sangue antes de começar a
tomar Nilemdo. Essa análise serve para verificar o funcionamento do seu
fígado.</p>
<p>Crianças e adolescentes</p>
<p>Não administre Nilemdo a crianças e adolescentes com menos de 18 anos
de idade. A utilização de Nilemdo não foi estudada neste grupo
etário.</p>
<p>Outros medicamentos e Nilemdo</p>
<p>Informe o seu médico ou farmacêutico se estiver a tomar, tiver tomado
recentemente, ou se vier a tomar outros medicamentos. Em particular,
informe o seu médico se estiver a tomar medicamentos que contenham
alguma das seguintes substâncias ativas:</p>
<ul>
<li><p>atorvastatina, fluvastatina, pitavastatina, pravastatina,
rosuvastatina, sinvastatina (utilizadas para baixar o colesterol e
conhecidas como estatinas). O risco de doenças musculares pode aumentar
ao tomar simultaneamente uma estatina e Nilemdo. Informe imediatamente o
seu médico sobre qualquer dor, sensibilidade ou fraqueza musculares
inexplicadas.</p></li>
<li><p>bosentano (utilizado para tratar um problema chamado hipertensão
da artéria pulmonar).</p></li>
<li><p>fimasartan (utilizado para tratar a tensão arterial alta e a
insuficiência cardíaca).</p></li>
<li><p>asunaprevir, glecaprevir, grazoprevir, voxilaprevir (utilizados
para tratar a hepatite C).</p></li>
</ul>
<p>Gravidez e amamentação</p>
<p>Não tome este medicamento se está grávida, a tentar engravidar ou se
pensa estar grávida, visto que há a possibilidade de o medicamento
afetar o bebé que irá nascer. Se engravidar enquanto estiver a tomar
este medicamento, consulte imediatamente o seu médico e deixe de tomar
Nilemdo.</p>
<ul>
<li>Gravidez Antes de iniciar o tratamento, deve confirmar que não está
grávida e que está a utilizar métodos contracetivos eficazes, conforme
aconselhado pelo seu médico. Se utilizar pílulas contracetivas e sofrer
um episódio de diarreia ou vómitos que dure mais de 2 dias, tem de
utilizar um método contracetivo alternativo (p. ex., preservativos,
diafragma) durante 7 dias após a resolução dos sintomas.</li>
</ul>
<p>Se, depois de ter iniciado o tratamento com Nilemdo, decidir que
gostaria de engravidar, informe o seu médico, visto que o seu tratamento
terá de ser alterado.</p>
<ul>
<li>Amamentação Não tome Nilemdo se estiver a amamentar porque não se
sabe se Nilemdo passa para o leite materno.</li>
</ul>
<p>Condução de veículos e utilização de máquinas</p>
<p>Os efeitos de Nilemdo sobre a capacidade de conduzir e utilizar
máquinas são nulos ou reduzidos.</p>
<p>Nilemdo contém lactose e sódio</p>
<p>Se foi informado pelo seu médico que tem intolerância a alguns
açúcares, contacte-o antes de tomar este medicamento.</p>
<p>Este medicamento contém menos do que 1 mmol (23 mg) de sódio por
comprimido ou seja, é praticamente “isento de sódio".</p>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. Como tomar nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Como tomar nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tome este medicamento exatamente como indicado pelo seu médico ou
farmacêutico. Fale com o seu médico ou farmacêutico se tiver
dúvidas.</p>
<p>A dose recomendada é de um comprimido uma vez por dia.</p>
<p>Engula o comprimido inteiro com alimentos ou entre refeições.</p>
<p>Se tomar mais Nilemdo do que deveria</p>
<p>Contacte imediatamente o seu médico ou farmacêutico.</p>
<p>Caso se tenha esquecido de tomar Nilemdo</p>
<p>Se constatar que se esqueceu:</p>
<ul>
<li><p>de tomar a dose tardiamente no dia, tome a dose de que se
esqueceu e tome a próxima dose à hora programada no dia
seguinte.</p></li>
<li><p>de tomar a dose do dia anterior, tome o seu comprimido à hora
programada e não tome outro para compensar a dose de que se
esqueceu.</p></li>
</ul>
<p>Se parar de tomar Nilemdo</p>
<p>Não pare de tomar Nilemdo sem a autorização do seu médico, dado que o
seu nível de colesterol pode voltar a subir.</p>
<p>Caso ainda tenha dúvidas sobre a utilização deste medicamento, fale
com o seu médico ou farmacêutico.</p>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Efeitos indesejáveis possíveis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Efeitos indesejáveis possíveis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Como todos os medicamentos, este medicamento pode causar efeitos
indesejáveis, embora estes não se manifestem em todas as pessoas.</p>
<p>Podem ocorrer efeitos indesejáveis com as seguintes frequências:</p>
<p>Frequentes (podem afetar até 1 em cada 10 pessoas)</p>
<ul>
<li><p>diminuição do número de glóbulos vermelhos (anemia)</p></li>
<li><p>aumento dos níveis de ácido úrico no sangue, gota</p></li>
<li><p>dor nos ombros, pernas, ou braços</p></li>
<li><p>resultados das análises ao sangue indicativos de anomalias no
fígado</p></li>
</ul>
<p>Pouco frequentes (podem afetar até 1 em cada 100 pessoas)</p>
<ul>
<li><p>diminuição da hemoglobina (uma proteína presente nos glóbulos
vermelhos que transporta oxigénio)</p></li>
<li><p>aumento dos níveis de creatinina e de azoto ureico no sangue
(análises laboratoriais da função renal)</p></li>
<li><p>diminuição da taxa de filtração glomerular (medição do
funcionamento dos rins)</p></li>
</ul>
<p>Comunicação de efeitos indesejáveis</p>
<p>Se tiver quaisquer efeitos indesejáveis, incluindo possíveis efeitos
indesejáveis não indicados neste folheto, fale com o seu médico ou
farmacêutico. Também poderá comunicar efeitos indesejáveis diretamente
através do sistema nacional de notificação mencionado no Apêndice V. Ao
comunicar efeitos indesejáveis, estará a ajudar a fornecer mais
informações sobre a segurança deste medicamento.</p>
 </div>"""      
        
* section[=].section[+]
  * title = "5. Como conservar nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Como conservar nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Manter este medicamento fora da vista e do alcance das crianças.</p>
<p>Não utilize este medicamento após o prazo de validade impresso no
blister e na embalagem, após EXP. O prazo de validade corresponde ao
último dia do mês indicado.</p>
<p>O medicamento não necessita de quaisquer precauções especiais de
conservação.</p>
<p>Não deite fora quaisquer medicamentos na canalização ou no lixo
doméstico. Pergunte ao seu farmacêutico como deitar fora os medicamentos
que já não utiliza. Estas medidas ajudarão a proteger o ambiente.</p>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Conteúdo da embalagem e outras informações"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Conteúdo da embalagem e outras informações"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Qual a composição de Nilemdo</p>
<ul>
<li><p>A substância ativa é o ácido bempedoico. Cada comprimido
revestido por película contém 180 mg de ácido bempedoico.</p></li>
<li><p>Os outros componentes são:</p></li>
</ul>
<ul>
<li>lactose mono-hidratada (consultar o fim da secção 2, em “Nilemdo
contém lactose e sódio")</li>
<li>celulose microcristalina (E460)</li>
<li>glicolato de amido sódico (Tipo A) (consultar o fim da secção 2, em
“Nilemdo contém lactose e sódio")</li>
<li>hidroxipropilcelulose (E463)</li>
<li>estearato de magnésio (E470b)</li>
<li>sílica coloidal anidra (E551)</li>
<li>poli(álcool vinílico) parcialmente hidrolisado (E1203), talco
(E553b), dióxido de titânio (E171), macrogol/PEG (E1521)</li>
</ul>
<p>Qual o aspeto de Nilemdo e conteúdo da embalagem</p>
<p>Os comprimidos revestidos por película são brancos a esbranquiçados,
ovais, com a gravação “180" num lado e “ESP" no outro lado. Dimensões do
comprimido: 13,97 mm × 6,60 mm × 4,80 mm.</p>
<p>Nilemdo é fornecido em blisters de plástico/alumínio em embalagens de
10, 14, 28, 30, 84, 90, 98 ou 100 comprimidos revestidos por película ou
em blisters de dose unitária em embalagens de 10 x 1, 50 x 1 ou 100 x 1
comprimidos revestidos por película.</p>
<p>É possível que não sejam comercializadas todas as apresentações no
seu país.</p>
<p>Titular da Autorização de Introdução no Mercado</p>
<p>Daiichi Sankyo Europe GmbH Zielstattstrasse 81379 Munich Alemanha</p>
<p>Fabricante</p>
<p>Daiichi Sankyo Europe GmbH Luitpoldstrasse 1 85276 Pfaffenhofen
Alemanha</p>
<p>Para quaisquer informações sobre este medicamento, queira contactar o
representante local do Titular da Autorização de Introdução no
Mercado:</p>
<p>België/Belgique/Belgien Daiichi Sankyo Belgium N.V.-S.A Tél/Tel:
+32-(0) 2 227 18 Lietuva Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808
0 България Daiichi Sankyo Europe GmbH тел.: +49-(0) 89 7808 0
Luxembourg/Luxemburg Daiichi Sankyo Belgium N.V.-S.A Tél/Tel: +32-(0) 2
227 18 Česká republika Zentiva, k.s. Tel: +420 267 241 Magyarország
Daiichi Sankyo Europe GmbH Tel.: +49-(0) 89 7808 0 Danmark Daiichi
Sankyo Europe GmbH Tlf: +49-(0) 89 7808 0 Malta Daiichi Sankyo Europe
GmbH Tel: +49-(0) 89 7808 0 Deutschland Daiichi Sankyo Deutschland GmbH
Tel: +49-(0) 89 7808 0 Nederland Daiichi Sankyo Nederland B.V. Tel:
+31-(0) 20 4 07 20 Eesti Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808
0 Norge Daiichi Sankyo Europe GmbH Tlf: +49-(0) 89 7808 0 Ελλάδα Daiichi
Sankyo Europe GmbH Τηλ: +49-(0) 89 7808 0 Österreich Daiichi Sankyo
Austria GmbH Tel: +43 (0) 1 485 86 42 0 España Daiichi Sankyo España,
S.A. Tel: +34 91 539 99 Polska Daiichi Sankyo Europe GmbH Tel.: +49-(0)
89 7808 0 France Daiichi Sankyo France S.A.S. Tél: +33 (0) 1 55 62 14
Portugal Daiichi Sankyo Portugal, Unip. LDA Tel: +351 21 4232Hrvatska
Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 România Daiichi Sankyo
Europe GmbH Tel: +49-(0) 89 7808 0 Ireland Daiichi Sankyo Ireland Ltd
Tel: +353-(0) 1 489 3Slovenija Daiichi Sankyo Europe GmbH Tel: +49-(0)
89 7808 0 Ísland Daiichi Sankyo Europe GmbH Sími: +49-(0) 89 7808 0
Slovenská republika Zentiva, a.s. Tel: +421 2 3918 3Italia Daiichi
Sankyo Italia S.p.A. Tel: +39-06 85 2Suomi/Finland Daiichi Sankyo Europe
GmbH Puh/Tel: +49-(0) 89 7808 0 Κύπρος Daiichi Sankyo Europe GmbH Τηλ:
+49-(0) 89 7808 0 Sverige Daiichi Sankyo Europe GmbH Tel: +49-(0) 89
7808 0 Latvija Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 United
Kingdom (Northern Ireland) Daiichi Sankyo Europe GmbH Tel: +49-(0) 89
7808 0</p>
<p>Este folheto foi revisto pela última vez em {mês de AAAA}.</p>
<p>Outras fontes de informação</p>
<p>Está disponível informação pormenorizada sobre este medicamento no
sítio da internet da Agência</p>
 </div>"""      





                    
Instance: bundlepackageleaflet-en-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for nilemdo Package Leaflet for language en"
Description: "ePI document Bundle for nilemdo Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4"
* entry[0].resource = composition-en-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4"
* entry[=].resource = mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4
                            
                    
Instance: bundlepackageleaflet-da-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for nilemdo Package Leaflet for language da"
Description: "ePI document Bundle for nilemdo Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4"
* entry[0].resource = composition-da-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4"
* entry[=].resource = mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4
                            
                    
Instance: bundlepackageleaflet-pt-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for nilemdo Package Leaflet for language pt"
Description: "ePI document Bundle for nilemdo Package Leaflet for language pt"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #pt

// Composition
* entry[0].fullUrl = "Composition/composition-pt-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4"
* entry[0].resource = composition-pt-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4"
* entry[=].resource = mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4
                            
                    



Instance: mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Nilemdo 180 mg film-coated tablets"
Description: "Nilemdo 180 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/20/1425/001 - 011"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Nilemdo 180 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: b0dbf83dbdd0b6f9d3c0904a5e7ceaa4ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "nilemdo"

* status = #current
* mode = #working

* title = "List of all ePIs associated with nilemdo"

* subject = Reference(mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#nilemdo "nilemdo"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4) // nilemdo en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4) // nilemdo da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-pt-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4) // nilemdo pt
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "pt"




Instance: List-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: List
Description: "ePI document List for nilemdo Package Leaflets"

* insert b0dbf83dbdd0b6f9d3c0904a5e7ceaa4ListRuleset
    